论文部分内容阅读
本文应用McAb-A－E花环试验对32例胃癌及直／结肠癌患者LAK细胞／rIL－2治疗前后外周血T淋巴细胞及其亚群进行检测。结果显示，胃癌患者治疗前与正常对照相比，CD_3+、CD_4+、CD_8+细胞和CD_4+／CD_8+比值均显著降低（P＜0.01）；直／结肠癌患者CD_3+、CD_4+细胞明显降低（P＜0．01），CD_8+细胞和CD_4+／CD_8+比值降低（P＜0．05）；治疗后与治疗前相比，胃癌和直／结肠癌患者CD_3+、CD_4+细胞显著增高（P＜0.01），胃癌患者的CD算细胞和CD_4／CD_8+比值显著增高（P＜0．01）。结果表明，在用LAK细胞／rIL－2治疗过程中，观察T淋巴细胞亚群变化，特别是对CD_4+／CD_8+比值的分析，可客观地反映患者的免疫功能状况，对指导免疫治疗及估计预后有一定临床价值。
In this study, the McAb-A-E rosette test was used to detect peripheral blood T-lymphocytes and their subpopulations before and after LAK cell/rIL-2 treatment in 32 patients with gastric cancer and colorectal cancer. The results showed that the ratios of CD3+, CD4+, CD8+, and CD4+/CD8+ were significantly lower in gastric cancer patients before treatment compared with normal controls (P<0.01); CD3+ and CD4+ cells in patients with gastric cancer were significantly lower (P<0.01). ), CD_8+ cells and CD_4+/CD_8+ ratio decreased (P<0.05); after treatment, compared with before treatment, CD3+ and CD4+ cells were significantly higher in gastric cancer and colorectal cancer patients (P<0.01). The ratio of cells and CD_4/CD_8+ was significantly higher (P<0.01). The results showed that the changes of T-lymphocyte subsets, especially the analysis of the ratio of CD4+/CD8+, can objectively reflect the patient’s immune function status during the treatment with LAK cells/rIL-2, and guide the immunotherapy and estimate the prognosis. Has a certain clinical value.